805 reports of this reaction
3.6% of all CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES reports
#4 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #4 most commonly reported adverse reaction for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, manufactured by Jazz Pharmaceuticals, Inc.. There are 805 FDA adverse event reports linking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES to PRODUCT DOSE OMISSION ISSUE. This represents approximately 3.6% of all 22,248 adverse event reports for this drug.
Patients taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 805 FDA reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 3.6% of all adverse event reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, making it a notable side effect.
If you experience product dose omission issue while taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.